Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

888 p38MAPK Inhibits Neutrophil Development through Phosphorylation of C/EBPα on Serine 21

Tuesday, December 9, 2008: 7:00 AM
Gateway Ballroom 104 - South (Moscone Center)

Miranda Buitenhuis, PhD1*, Christian R. Geest, MSc1*, Annemieke G. Laarhoven, BSc1*, Marrie C.A. Bruin, MD, PhD2*, Marc B. Bierings, MD, PhD2*, Edo Vellenga, MD, PhD3 and Paul J. Coffer, PhD1

1Dept. of Immunology, University Medical Center, Utrecht, Netherlands
2Dept. of Pediatric Hematology, University Medical Center Utrecht, Utrecht, Netherlands
3University Hospital Groningen, Groningen, Netherlands

Many extracellular stimuli regulate growth, survival and differentiation responses through activation of the dual specificity kinase MAPK kinase 3 (MKK3) and its downstream effector p38 Mitogen-Activated Protein Kinase (MAPK). Using CD34+ hematopoietic progenitor cells, here we describe a novel role for MKK3-p38MAPK in the regulation of myelopoiesis. Inhibition of p38MAPK utilising the pharmacological inhibitor SB203580, enhanced neutrophil development ex-vivo, but conversely reduced eosinophil differentiation. In contrast, constitutive activation of MKK3 dramatically inhibited neutrophil differentiation. Transplantation of β2-microglobulin-/- NOD/SCID mice with CD34+ cells ectopically expressing constitutively active MKK3 resulted in reduced neutrophil differentiation in vivo, whereas eosinophil development was enhanced. Inhibitory phosphorylation of C/EBPα on serine 21 was induced upon activation of p38MAPK. Moreover, ectopic expression of a non-phosphorylatable C/EBPα mutant was sufficient to abrogate MKK3 induced inhibition of neutrophil development. Furthermore, treatment of CD34+ progenitors from patients with severe congenital neutropenia with SB203580 restored neutrophil development. These results establish a novel role for MKK3-p38MAPK in the regulation of lineage choices during myelopoiesis through modulation of C/EBPα activity. This signaling module may thus provide an important therapeutic target in the treatment of bone marrow failure.

Disclosures: No relevant conflicts of interest to declare.

Previous Presentation | Next Presentation >>

*signifies non-member of ASH